Loading...
XKRX
206640
Market cap159mUSD
Jul 10, Last price  
11,410.00KRW
1D
4.11%
1Q
-0.09%
Jan 2017
-39.22%
IPO
-42.95%
Name

Boditech Med Inc

Chart & Performance

D1W1MN
XKRX:206640 chart
P/E
10.59
P/S
1.55
EPS
1,077.76
Div Yield, %
1.37%
Shrs. gr., 5y
-1.20%
Rev. gr., 5y
2.37%
Revenues
162.02b
+17.27%
39,821,415,29854,974,499,12052,593,956,50066,204,377,38072,798,657,000144,131,042,000157,707,960,000118,076,843,000134,219,240,000138,160,173,000162,018,969,000
Net income
23.68b
-13.15%
-1,970,266,06412,620,723,299-2,147,728,007-1,690,693,84411,649,992,00045,489,251,00044,366,589,00024,151,534,00025,946,636,00027,260,388,00023,675,990,000
CFO
22.08b
-11.24%
9,632,299,67611,790,575,204886,736,1475,314,864,01917,242,231,86544,642,883,00049,927,140,00023,068,408,00034,299,696,00024,878,655,00022,081,113,000
Dividend
Mar 31, 2025150 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay analyzers designed to quantify analytes in various biological samples like blood, urine, and other body fluids. Key offerings include the ichroma II, an automated or semi-automated system for precise analyte measurement; AFIAS-6 and AFIAS-1, automated fluorescent immunoassay systems also designed for accurate quantification of targeted analytes; and the ichroma-50, an automatic immunoassay analyzer that determines analyte concentrations in bodily fluids. Additionally, the ichroma M2 is a portable analyzer suited for centralized hospital laboratories and physician's clinics, compatible with in-vitro diagnostic immunofluorescent assay kits for screening, monitoring, and routine examinations. Beyond these, Boditech Med also provides specialized diagnostic instruments such as the Ichroma TRIAS Reader, which measures targeted analyte concentration from diverse samples including blood, nasal, and nasopharyngeal swabs; the Hemochroma PLUS for quantitative total hemoglobin testing in blood; the i-chamber, an auxiliary component for ichroma systems; and the HandyRay, an innovative laser device facilitating needle-free capillary blood sampling. These diagnostic solutions address a broad spectrum of medical fields, including cardiac health, oncology, diabetes management, hormone analysis, infection, infectious diseases, gastrointestinal issues, and rheumatoid arthritis. Boditech Med Inc. distributes its products globally through a network of approximately 100 sales agencies.
IPO date
Dec 29, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT